Le Lézard
Classified in: Health
Subjects: NEW PRODUCTS/SERVICES, PARTNERSHIPS

I-MED Pharma Becomes the Authorized Canadian Distributor for the OrCam MyEye 2


MONTREAL, April 10, 2019 (GLOBE NEWSWIRE) -- I-MED Pharma, Inc., a Canadian company specializing in dry eye diagnosis and management is proud to announce the signing of an authorized Canadian distribution agreement with OrCam for its MyEye 2 assistive technology device for the blind and visually impaired.

A video accompanying this announcement is available at   https://www.youtube.com/watch?v=EUKlUo3j18g&t=10s

The OrCam MyEye 2 is a tiny, portable, artificial vision device for the blind and visually impaired that uses cutting-edge technology that is simple and intuitive.  With its lightweight smart camera, it can instantly read written or digital text aloud, recognize faces, money notes, product labels and much more.  Using simple hand gestures, its ease-of-use makes it ideal for children, adults and the elderly, no matter what level of vision they have.  It can be used at home, at work or at school, and can also help people with learning disabilities, such as dyslexia.

Philipp Binder, Vice-President of I-MED Pharma stated, "The OrCam MyEye 2 is a fascinating device that offers a blind or visually impaired person of any age the ability to enjoy a book, recognize faces, identify products and so much more.  It ultimately makes people feel more comfortable in social situations and gives them back their independence.  We are proud to be able to offer this amazing assistive technology device to Canadians."

Gil Artzyeli, VP Strategic Alliances at OrCam commented, "OrCam is proud to have I-Med-Pharma as its Canadian partner.  OrCam's cutting edge AI technology empowers the blind and visually impaired of all ages to be more independent, active and engaged. Together, with I-MED Pharma's expertise in ophthalmology and optometry, we can reach out to thousands of Canadians who can benefit from the latest assistive technology available for the blind and visually impaired."

About I-MED Pharma

I-MED Pharma is a privately held Canadian company, headquartered in Montreal, Quebec, servicing Canadian ophthalmologists, optometrists and the global eye care community. Established thirty years ago, I-MED Pharma Inc. creates and distributes innovative medical, surgical and veterinary eye care products. It continually researches, develops and sources the most effective and advanced solutions to eye disorders like cataracts, corneal degenerations, glaucoma, dry eye and meibomian gland disease.

I-MED Pharma is proud to have been at the forefront of managing Dry Eye Syndrome as a serious disease and invests heavily in researching and developing effective dry eye products.  I-MED Pharma's ocular surface disease product range includes dry eye drops, ocular hygiene, nutrition, therapeutic accessories and ocular occlusion devices.

About OrCam

OrCam's mission is to harness the power of artificial vision by incorporating pioneering technology into a wearable platform which improves the lives of individuals who are blind, visually impaired, and have reading difficulties.  OrCam was jointly founded in 2010 by Prof. Amnon Shashua and Mr. Ziv Aviram, who are also the co-founders of Mobileye, the collision avoidance system leader and autonomous driving innovator.

For more information, please email [email protected] or visit www.imedpharma.com.


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: